Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly and Company has received approval from the US Food and Drug Administration for Trulicity (dulaglutide) as a treatment option for adults with type 2 diabetes.
Subscribe to our email newsletter
The once-weekly subcutaneous injection, Trulicity is designed to improve glycemic control (blood sugar levels), along with diet and exercise, in these patients.
Trulicity is not recommended as first-line therapy for patients inadequately controlled on diet and exercise. The drug has also been submitted to the European Medicines Agency and other regulatory bodies.
The company intends to launch Trulicity 0.75mg and 1.5mg single-dose pens for adults in the US later this year.
Lilly Diabetes president Enrique Conterno said: "Lilly now has treatment options in several classes of diabetes medications: orals, GLPs and insulin.
"Trulicity will help grow the GLP-1 receptor agonist class as a new choice for adults with type 2 diabetes."
Safety and effectiveness of the drug was evaluated in six clinical trials in which 3,342 patients with type 2 diabetes received Trulicity.
According to FDA, patients receiving Trulicity had an improvement in their blood sugar control as observed with reductions in HbA1c level (hemoglobin A1c is a measure of blood sugar control).
The drug has been studied as a stand-alone therapy and in combination with other type 2 diabetes therapies, including metformin, sulfonylurea, thiazolidinedione, and prandial insulin.